Furthermore, urine circulating tumor DNA markers (i.e., mutated TP53, methylated RASSF1a, and GSTP1) were able to detect early-stage HCC patients, especially those with low AFP levels [37]. Here, GSTP1 is linked to hepatocellular carcinoma.